Beyond the Dual Agonist: The Pharmacodynamics of Retatrutide (LY3437943) and the Role of the Glucagon Receptor
As the landscape of incretin-based therapeutics evolves, attention has shifted from mono-agonists (GLP-1) to dual-agonists (GLP-1/GIP) and now to tri-agonists. Retatrutide (LY3437943) represents a novel class of peptide therapeutic: a...
Read more...
